Compare Natera Inc. Common Stock (NTRA) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Riot Platforms Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Riot Platforms Inc trades at $14.68 (market cap $6.26B). The key difference: Natera Inc. Common Stock is far larger — about 9.1× Riot Platforms Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Riot Platforms Inc for 16 Days on average.
| NTRA | RIOT | |
|---|---|---|
Market Cap | $57.03B | $6.26B |
Volume | 1,131,157 | 19,608,398 |
Sector | Health | Financials |
52-Week High | $425.64 | $28.67 |
52-Week Low | $179.42 | $11.83 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $56.18B | $6.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
RIOT Platforms trades at $16.67, up 1.21% with a bearish technical signal despite bullish oscillators. The company reported significant losses with a net income margin of -196.28% and negative cash flow from operations of -$573 million in 2025. Recent strategic shift to data center leasing secured $9.8 billion in contracted revenue through 2048, attracting major tenants like AMD.
Analyst consensus remains strongly bullish with 94.74% buy ratings and a $31.64 price target, suggesting substantial upside potential. Key risks include persistent negative profitability, high valuation multiples, and execution challenges in the AI infrastructure transition. The stock faces near-term pressure from consecutive earnings misses but offers long-term growth potential through its power capacity assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
